BioSpace News Archive

Merck announced that the pivotal Phase 3 KEYNOTE-042 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC, including nonsquamous or squamous histologies) met its primary endpoint of overall survival (OS).

Cellect Biotechnology Ltd. announced that it has successfully completed the proof of concept testing of its first in type new product prototype, ApoTainer™ using Cellect’s FasL-coated magnetic beads for maximizing efficacy and scalability of stem cell based products’ manufacturing.

GNC Holdings, Inc. (NYSE: GNC) (the “Company”) will release results for the first quarter of 2018 before the market opens on April 26, 2018.

Outcome of discussions between its U.S. joint venture, ReGenTree LLC, and the FDA regarding the results of the completed phase 3 clinical trial and the future development requirements for a New Drug Application submission of RGN-259, a novel drug candidate to treat dry eye syndrome.

Company strengthens leadership team with appointments and promotions in key roles for next stage of growth.

Acerus had previously planned for the Canadian launch of URIVARX® in the second half of 2018, but the Company has arranged for the product to be available in Canada via the Innovus supply chain.

Close to half of drug discovery research will be contracted to CROs is a good estimate based on in-the-know contacts and research.

GigaGen, Inc. announced that David Johnson, Ph.D., chief executive officer, will present data from the company’s proprietary Surge platform at the American Association for Cancer Research (AACR) Annual Meeting 2018.

Omnicell, Inc. announced that Scott Seidelmann has joined the Company as Chief Commercial Officer beginning this month.

Intezyne announced that it has promoted Bradford Sullivan, PhD to Director, Chemistry, Manufacturing, and Controls (CMC).